2013
DOI: 10.2340/00015555-1391
|View full text |Cite
|
Sign up to set email alerts
|

Brooke-Spiegler Syndrome Associated with Ulcerative Rectosigmoiditis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2014
2014
2017
2017

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 14 publications
(36 reference statements)
0
4
0
Order By: Relevance
“…1,7 It exerts a tumor suppressor effect by negative regulation of the intracellular signalling pathways of NF-κB, JNK and Wnt. 4,5 CYLD mutations ultimately increase NF-κB expression, leading to resistance to apoptosis and facilitating tumor development. 4,5 There are currently at least 93 known germline mutations of CYLD, most of them involving its 3' terminal, which translates the catalytic domain of the enzyme (exons 8-20).…”
Section: Discussionmentioning
confidence: 99%
See 3 more Smart Citations
“…1,7 It exerts a tumor suppressor effect by negative regulation of the intracellular signalling pathways of NF-κB, JNK and Wnt. 4,5 CYLD mutations ultimately increase NF-κB expression, leading to resistance to apoptosis and facilitating tumor development. 4,5 There are currently at least 93 known germline mutations of CYLD, most of them involving its 3' terminal, which translates the catalytic domain of the enzyme (exons 8-20).…”
Section: Discussionmentioning
confidence: 99%
“…4,5 CYLD mutations ultimately increase NF-κB expression, leading to resistance to apoptosis and facilitating tumor development. 4,5 There are currently at least 93 known germline mutations of CYLD, most of them involving its 3' terminal, which translates the catalytic domain of the enzyme (exons 8-20). 3 About 90% of the tumor-eliciting mutations result in a truncated CYLD protein and are mainly of frameshift or nonsense type.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations